NDRA

ENDRA Life Sciences Inc

Add to Watchlist

Advanced Chart

4.130

-0.21(-4.839%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

4.130

Open

4.040

VWAP

4.05

Vol

18.85K

Mkt Cap

3.20M

Low

4.020

Amount

76.31K

EV/EBITDA(TTM)

Total Shares

17.14M

1.14M

EV/OCF(TTM)

P/S(TTM)

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-2.670

-110.6%

-2.670

-72.01%

-2.270

-98.38%

Estimates Revision

The market is revising No Change the revenue expectations for ENDRA Life Sciences Inc. (NDRA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 19.71%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+19.71%

In Past 3 Month

1 Analyst Rating

1013.80% Upside

Wall Street analysts forecast NDRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NDRA is 46.00 USD with a low forecast of 46.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

1013.80% Upside

Current: 4.130

Low

46.00

Averages

46.00

High

46.00

1013.80% Upside

Current: 4.130

Low

46.00

Averages

46.00

High

46.00

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$75 → $50

2025-04-21

Reason

Ascendiant Capital

Edward Woo

Price Target

$75 → $50

2025-04-21

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for ENDRA Life Sciences Inc (NDRA.O) is -0.43, compared to its 5-year average forward P/E of -2.39. For a more detailed relative valuation and DCF analysis to assess ENDRA Life Sciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.39

Current PE

-0.43

Overvalued PE

0.19

Undervalued PE

-4.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.63

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.86

Undervalued EV/EBITDA

-2.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

27.89

Current PS

0.00

Overvalued PS

98.65

Undervalued PS

-42.86